# Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

> **NCT05932199** · PHASE1,PHASE2 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 52 (estimated)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Durvalumab / tremelimumab
- **DRUG:** Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab

## Key facts

- **NCT ID:** NCT05932199
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-03
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932199, "Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05932199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*